MIRA: חוב כולל להון MIRA Pharmaceuticals

MIRA Pharmaceuticals (MIRA) develops treatments for depression and pain, with future profits relying on the sale of patented cannabinoids through insurance companies. Market price action shows that the total debt-to-equity ratio is 0.00. High barriers to entry in this niche are ensured by strict FDA and DEA oversight, as well as exclusive rights to chemical formulas.

This ratio determines the financing structure by comparing total liabilities to net assets to assess the business's degree of dependence on debt capital. By analyzing the proportion of total debt to equity, an investor can understand how sustainably MIRA Pharmaceuticals (MIRA) finances the development of proprietary cannabinoids amid stringent regulatory oversight from the FDA and DEA, which limits the entry of new competitors into the niche.